Significant advances have been made in the treatment of non-small cell lung cancer (NSCLC), the most common form of lung cancer. The latest trial updates in oncogene-targeted therapy for patients with advanced ALK-positive NSCLC were presented during the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

In a planned interim analysis of the Phase III CROWN trial, lorlatinib significantly improved progression-free survival compared with crizotinib. Additionally, insights from sub-analyses of the Phase III ALTA 1L study support the evidence of intracranial efficacy with brigatinib for patients with ALK-positive NSCLC as well as associated quality of life data.

In this podcast, Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, details recent results of both the CROWN and ALTA-1L trials and sheds light on new potential NSCLC front-line treatments.

This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).